Phase I Clinical Trial of AZD2284, AZD2287, and AZD2275
/in Clinical Trial, Metastatic, Phase 1/by MaxBreaking Resistance: A Dual-Pathway Drug Shows Promise for Advanced Prostate Cancer
/in Preclinical Research/by MaxEnzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial
/in Post-hoc, Retrospective studies/by MaxNewsletter 11/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Tired of this rain! Today’s update highlights three promising clinical trials alongside two intriguing preclinical studies. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it […]
Phase 1/2 trial: Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFutureChem Launches Phase 3 Trial for Novel PSMA-Targeted Radiopharmaceutical FC705
/in Clinical Trial, Metastatic, Phase 3/by MaxEVM16: A Personalized mRNA Cancer Vaccine Enters Clinical Trials
/in Clinical Trial, Metastatic, Phase 1/by MaxNew Research Unlocks Potential for Immunotherapy in Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026
- Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC April 21, 2026
- Phase 1/2 RAISIC‑1 Trial: PTT‑4256 in Advanced Solid Tumors April 20, 2026